NCT03136237 is a Phase 1 clinical trial of BCX7353 in Hereditary Angioedema, sponsored by BioCryst Pharmaceuticals.

Who is sponsoring NCT03136237?

NCT03136237 is sponsored by BioCryst Pharmaceuticals.

What drugs are being tested in NCT03136237?

Interventions in NCT03136237: BCX7353, Digoxin, BCX7353 + digoxin, Rosuvastatin, rosuvastatin + BCX7353, Cyclosporine + BCX7353.

What condition does NCT03136237 study?

NCT03136237 studies Hereditary Angioedema.

Is NCT03136237 still recruiting?

NCT03136237 is currently completed. Last updated 26 October 2017.

Last reviewed 2017-10-26 · How we verify

NCT03136237

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions

Completed Phase 1 Last updated 26 October 2017

What this trial tests

Phase 1 trial testing BCX7353 in Hereditary Angioedema in 54 participants. Completed in 15 August 2017.

Timeline

17 February 2017

Primary endpoint
15 August 2017

15 August 2017

Quick facts

Lead sponsor	BioCryst Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	17 February 2017
Primary completion	15 August 2017
Estimated completion	15 August 2017
Sites	1 location across United Kingdom

Drugs / interventions tested

BCX7353
Digoxin (digoxin) — full drug profile →
BCX7353 + digoxin
Rosuvastatin (rosuvastatin) — full drug profile →
rosuvastatin + BCX7353
Cyclosporine + BCX7353 — full drug profile →

Conditions studied

Hereditary Angioedema — all drugs for Hereditary Angioedema →

Sponsor

BioCryst Pharmaceuticals — full company profile →

Who can join

Adults 18 to 55, any sex, with Hereditary Angioedema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, three part study to evaluate the effect of BCX7353 on drug transporters as well as the effect of an inhibitor of drug transport on BCX7353.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of BCX7353

Trials testing the same drug.

NCT03472040 — A Long Term Safety Study of BCX7353 in Hereditary Angioedema · Phase 2, PHASE3 · completed
NCT03240133 — Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema · Phase 2 · completed
NCT03202784 — A Relative Bioavailability Study of Two Formulations of BCX7353 · Phase 1 · completed

Other recruiting trials for Hereditary Angioedema

Currently open trials in the same condition.

NCT06960213 — STOP-HAE: A Phase 3 Study of ADX-324 in HAE · Phase 3 · recruiting
NCT06806657 — Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab · Phase 4 · recruiting
NCT06573723 — Institutional Registry of Rare Diseases · recruiting
NCT05691361 — Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients · Phase 1, PHASE2 · active not recruiting
NCT05505916 — An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angio · Phase 3 · active not recruiting

Other BioCryst Pharmaceuticals trials

Trials by the same sponsor.

NCT06100900 — Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) · Phase 1 · completed
NCT05741346 — Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria · Phase 2 · terminated
NCT05162066 — Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Imm · Phase 2 · terminated
NCT05116774 — BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 In · Phase 2 · terminated
NCT05116787 — BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement In · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03136237 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BioCryst Pharmaceuticals
Last refreshed: 26 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03136237.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing